REVELATION BIOSCIENCES, INC. SEC 10-Q Report

Revelation Biosciences, Inc., a biotechnology company focused on developing therapeutics that modulate the innate immune system, has released its Form 10-Q report for the first quarter of 2025. The report provides a detailed overview of the company's financial performance and operational highlights, reflecting its ongoing efforts in product development and research activities.

Financial Highlights

• Net Loss: The company reported a net loss of $2.1 million for the three months ended March 31, 2025, compared to a net loss of $2.7 million for the same period in 2024, indicating a reduction in net loss by $0.6 million.
• Net Loss Per Share, Basic and Diluted: The net loss per share improved significantly from $(39.37) in the prior year period to $(2.11) in the current period, reflecting the impact of the reverse stock split and changes in the number of shares outstanding.
• Loss from Operations: The loss from operations increased slightly by $0.2 million compared to the prior year, primarily due to increased research and development expenses.
• Total Operating Expenses: Total operating expenses increased by $0.2 million, driven by higher research and development costs and general and administrative expenses.

Business Highlights

• Product Development Focus: Revelation Biosciences, Inc. is focused on developing a pipeline of potential high-value products based on its proprietary formulation Gemini, which is designed to rebalance inflammation to optimize health. The current programs include GEM-AKI for acute kidney injury, GEM-CKD for chronic kidney disease, GEM-PSI for post-surgical infection, and GEM-PBI for infection prevention in severe burn patients.
• Research and Development Activities: The company has devoted substantial resources to research and development, with a focus on clinical studies for its product candidates. Research and development expenses increased due to higher clinical study expenses and personnel costs.
• Operational Challenges: The company has incurred recurring losses since inception and expects to continue incurring significant operating and net losses as it progresses with product development and commercialization efforts.
• Future Outlook: Revelation anticipates that its current cash and cash equivalents will not be sufficient to sustain operations within one year, raising substantial doubt about its ability to continue as a going concern. The company plans to seek additional funding through public or private equity or debt financings.
• Management's Strategy: The management is focused on continuing the research and development of its product candidates, initiating clinical studies, and seeking regulatory and marketing authorizations. The company is also looking to attract and retain skilled personnel to support its growth.
• Segment Information: The company operates in one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
• Stock-Based Compensation: Revelation has implemented a 2021 Equity Incentive Plan to attract and retain employees, with stock-based compensation expenses recorded for RSA awards and other stock options.
• Reverse Stock Split: On January 28, 2025, the company effected a 1-for-16 reverse stock split of its outstanding shares of common stock to better align its stock price with market expectations.

SEC Filing: REVELATION BIOSCIENCES, INC. [ REVB ] - 10-Q - May. 08, 2025